Mtrex IV Injection or Infusion IV Injection 50 mg/2 ml is a Product of the Generic Methotrexate

What Is Mtrex IV Injection or Infusion IV Injection 50 mg/2 ml Indications and Uses?

Neoplastic Diseases : Treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole In acute lymphoblastic leukemia Used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas ... Read more Neoplastic Diseases : Treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole In acute lymphoblastic leukemia Used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas Treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T-cell lymphoma) and lung cancer, particularly squamous cell and small cell types. Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis : Indicated in the management of selected adults with severe, active rheumatoid arthritis, or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs) Psoriasis : Indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy.

Pharmacology (Source, Chemical and Physical Composition) Of Mtrex IV Injection or Infusion IV Injection 50 mg/2 ml

Mtrex IV Injection or Infusion IV Injection 50 mg/2 ml (Methotrexate) inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. When cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues. In psoriasis, the rate of production of epithelial cells in the skin is greatly increased over normal skin. This difference in proliferation rates is the basis for the use of methotrexate to control the psoriatic process.

Drug Interactions of Mtrex IV Injection or Infusion IV Injection 50 mg/2 ml

NSAIDs: Should not be administered prior to or concomitantly with high doses of Mtrex, such as used in the treatment of osteosarcoma Salicylates, Phenylbutazone, Phenytoin and Sulfonamides: Toxicity may be increased Penicillin, Theophylline, Probenecid, Azathioprine, Retinoids, Sulfasalazine: Should be closely monitored for possible increased risk of hepatotoxicity Cisplatin: Caution must be exercised if high-dose Mtrex is administered in combination Mercaptopurine: Mtrex increases the plasma levels of mercaptopurine Tetracycline, Chloramphenicol and Nonabsorbable Broad Spectrum Antibiotics: May decrease intestinal absorption of Mtrex Vitamin preparations containing folic acid or its derivatives: Decreases responses to systemically administered Mtrex Trimethoprim/Sulfamethoxazole: Rarely increases bone marrow suppression

Side Effects of Mtrex IV Injection or Infusion IV Injection 50 mg/2 ml

The most frequently reported adverse reactions include ulcerative stomatitis, leukopenia, nausea and abdominal distress Other frequently reported adverse effects are malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection Mtrex has been reported to cause impairment of fertility, oligospermia and menstrual dysfunction in humans, during and for a short period after cessation of therapy

Precautions And Warnings for Mtrex IV Injection or Infusion IV Injection 50 mg/2 ml

Mtrex formulations and diluents containing preservatives must not be used for intrathecal or high dose Mtrex therapy It is necessary to follow patients on Mtrex closely for toxic effects If adverse reactions occur, the drug should be reduced in dosage or discontinued and appropriate corrective measures should be taken. If necessary, this could include the use of leucovorin calcium If Mtrex therapy is reinstituted, it should be carried out with caution, with adequate consideration of further need for the drug and increased alertness as to possible recurrence of toxicity Persistent liver function test abnormalities, &/or depression of serum albumin may be indicators of serious liver toxicity & require evaluation Folate deficiency: May increase Mtrex toxicity

Use During Pregnancy and Lactation

US FDA Pregnancy Category X. Mtrex IV Injection or Infusion IV Injection 50 mg/2 ml (Methotrexate) should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus. It is contraindicated in nursing mothers.

Therapeutic Class

Antidote preparations, Immunosuppressant

Storage Conditions of It

Store at a temperature not exceeding 30°C in a dry place. Protect from light & moisture. Thanks for using MedEx! How would you rate your experience so far?